The prothrombotic potential of platelet factor 4
- PMID: 20206875
- DOI: 10.1016/j.ejim.2009.11.007
The prothrombotic potential of platelet factor 4
Abstract
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initiated by heparin administration. It is caused by the formation of pathogenic antibodies to complexes of platelet factor-4 (PF4) and heparin on platelet surfaces that cause platelet activation, aggregation and thrombosis. There has been intense research on this intriguing, drug-related thrombocytopenia explaining several characteristic aspects of this condition. However, prothrombotic potential of the key player, PF4 has not been investigated in many studies although it has been shown to be critical in monocyte chemotaxis, monocyte-platelet interaction, and megakaryocyte suppression, all of which can contribute to the pathophysiology of HIT. This article explains the important role of PF4 released during platelet activation with the administration of heparin in the pathogenesis of thrombocytopenia and thrombosis in HIT.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.Thromb Haemost. 1995 Jan;73(1):21-8. Thromb Haemost. 1995. PMID: 7740492
-
Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.J Clin Apher. 2007 Feb;22(1):31-6. doi: 10.1002/jca.20109. J Clin Apher. 2007. PMID: 17285619 Review.
-
An overview of the heparin-induced thrombocytopenia syndrome.Semin Thromb Hemost. 2004 Jun;30(3):273-83. doi: 10.1055/s-2004-831039. Semin Thromb Hemost. 2004. PMID: 15282649 Review.
-
Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model.J Thromb Haemost. 2006 Dec;4(12):2687-94. doi: 10.1111/j.1538-7836.2006.02201.x. Epub 2006 Sep 8. J Thromb Haemost. 2006. PMID: 16961586
-
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis.Thromb Res. 2010 Apr;125(4):292-6. doi: 10.1016/j.thromres.2009.11.023. Epub 2009 Dec 9. Thromb Res. 2010. PMID: 20004006 Review.
Cited by
-
Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data.J Thromb Thrombolysis. 2011 Aug;32(2):201-8. doi: 10.1007/s11239-011-0590-9. J Thromb Thrombolysis. 2011. PMID: 21562837 Review.
-
Multifaceted prospects of nanocomposites for cardiovascular grafts and stents.Int J Nanomedicine. 2015 Apr 7;10:2785-803. doi: 10.2147/IJN.S80121. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25897223 Free PMC article. Review.
-
Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis.J Endocrinol Invest. 2016 Feb;39(2):185-9. doi: 10.1007/s40618-015-0348-x. Epub 2015 Jul 5. J Endocrinol Invest. 2016. PMID: 26142741
-
Platelets as a potential new immune coordinator in T cell-mediated aplastic anemia.Front Oncol. 2025 Jun 9;15:1568169. doi: 10.3389/fonc.2025.1568169. eCollection 2025. Front Oncol. 2025. PMID: 40552264 Free PMC article. Review.
-
Effects of ulinastatin on coagulation in high-risk patients undergoing off-pump coronary artery bypass graft surgery.Korean J Anesthesiol. 2013 Feb;64(2):105-11. doi: 10.4097/kjae.2013.64.2.105. Epub 2013 Feb 15. Korean J Anesthesiol. 2013. PMID: 23459312 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous